Trial Profile

A proof-of-concept clinical trial of QR-411a for Usher syndrome PE40

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 05 Feb 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs QR 411a (Primary)
Indications Usher syndromes
Focus Adverse reactions; Proof of concept

Most Recent Events

05 Feb 2019 New trial record
29 Jan 2019 According to the ProQR Therapeutics, updates from the study announced in ProQR Vision 2023 strategy and will be presented at an R&D day event.
29 Jan 2019 According to a ProQR Therapeutics media release, the company is planning to start the trial in 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com